One of our clients was recently profiled in The Sydney Morning Herald, a newspaper local in Australia, and we always like to celebrate our clients’ successes. LeafCann is an upstart medical marijuana business in the state of Victoria, Australia, on the leading edge of marijuana reform in that country.
Its founder, Chris Nasr, approached us in 2015 for our expertise in regulatory compliance for medical marijuana – before regulations were even being proposed – for the Australian market. Being aware of the great business potential in the years to come, and driven by his family’s experience with pain and suffering, Chris has shown great passion in his new business.
There are challenges coming to market with medical marijuana in Australia. First and foremost, despite proposed regulations at the federal level, there is no legal framework yet. The Greens political party had pushed forward a Bill in the Senate in 2014, which was essentially a high level proposal on how a regulatory scheme could be set up for the country. In late 2015, the state of Victoria started advancing its own leglislation separate from the Commonwealth; under Australian law, individual states can opt out of certain federal restrictions, including the regulation of controlled substances. Victoria began accepting applications for test market cultivation and manufacturing, and which is where we came in.
LeafCann approach our company to petition the Victorian Commission on their behalf, to allow their company to cultivate and manufacture medical marijuana in Victoria. The application is still pending, but is in late stages of review. NHP Consulting recruited expertise in Canada including security consulting to provide LeafCann with a high level petition outlining how LeafCann would cultivate and manufacture medical marijuana in Victoria. Because Canada currently has the most complex regulatory requirements in the world for the cultivation and manufacturing of medical marijuana, we were seen as a great fit for helping them advance their cause in Australia.
Currently LeafCann is discussing investor opportunities, and for more information please contact NHP Consulting and we can make an introduction.
At present, medical marijuana in Victoria has a soft start, with product being sold through pharmacies (with supply managed by the government), and only under a specific set of conditions (e.g., epilepsy in childhood). Also, the Victorian Commission is not recommending the sale of dried cannabis, but rather the crude product would be used to manufacture various pharmaceutical dosage forms including oils and tinctures. Manufacturing would need to be compliant within the Therapeutic Goods Administration framework similar to a pharmaceutical operation. The Commonwealth has already amended the Narcotic Drugs Act which recently passed the senate, and so the path forward for a national scheme of medical marijuana production and manufacturing is being finalized in the background.
Contact us for more information on how NHP Consulting can assist in all areas of health product manufacturing. Our company is based in Canada, and has regulatory specialists in Australia.